- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03635879
Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides
September 25, 2018 updated by: Cerecin
A Phase 1, Single-Center, Pilot, Single-Dose, 6-Way Crossover Study to Compare Six Formulations of Medium Chain Triglycerides on the Pharmacokinetics of Ketone Body Production
This is a Phase I, open label, randomized, 6-way crossover, pilot PK study
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
12 healthy, male subjects enrolled, subject will be randomized to receive a single dose of one of six treatment, with a 2 day washout in between each dosing period.
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy, adult, male 18 55 years of age, inclusive, at Screening.
- Continuous non smoker who has not used nicotine containing products for at least 3 months prior to Day -1 of Period 1 and throughout the study based on self-reporting.
- Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening.
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ the upper limit of normal and triglyceride levels must be < 250 mg/dL.
- Hemoglobin levels ≥ the lower limit of normal at Screening and Day -1 of Period 1.
- A non vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Day -1 of Period 1. A subject who has been vasectomized less than 4 months prior to Day -1 of Period 1 must follow the same restrictions as a non vasectomized male).
- Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.
Exclusion Criteria:
- Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
- History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
- History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- History or presence of alcoholism or drug abuse within the past year prior to Day -1 of Period 1.
- History or presence of galactosemia or hypersensitivity or idiosyncratic reaction to the study drugs, related compounds, milk, palm or coconut oil, or soy.
- History or presence of symptomatic diverticular disease, uncontrolled gastroesophageal reflux disease, ulcers, inflammatory bowel disease, irritable bowel syndrome or recurrent diarrhea, or gout.
- Positive urine drug results at Screening or Check-in.
- Positive alcohol results at Screening or Check-in. One repeat assessment is permitted.
- Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
- Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at Screening. One repeat assessment is permitted.
- Seated heart rate is lower than 40 bpm or higher than 99 bpm at Screening.
- QTcF interval is >460 msec or subject has ECG findings deemed abnormal with clinical significance by the PI or designee at Screening.
- Estimated creatinine clearance ≤ 80 mL/min at Screening.
- Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to Day -1 of Period 1 and throughout the study. Acetaminophen (up to 2 g per 24 hours) may be permitted during the study.
- Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 28 days prior to Day -1 of Period 1 and throughout the study.
- Has been following a ketogenic diet, in the opinion of the PI or designee, within 2 weeks prior to Day -1 of Period 1.
- Is lactose intolerant.
- Is unable to complete the standard breakfast prior to dosing on Day 1 of each Period.
- Donation of blood or significant blood loss within 56 days prior to Day -1 of Period 1.
- Plasma donation within 7 days prior to Day -1 of Period 1.
- Participation in another clinical study within 28 days prior to Day -1 of Period 1. The 28-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day -1 of Period 1 of the current study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: MCTprocal medical food
Vitaflo MCTprocal, single dose (20 g MCT)
|
32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
|
Active Comparator: Milk/tricaprilin oil blend
Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
|
154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
|
Active Comparator: AC-1207
AC-1207 liquid, single dose (20 g tricaprilin)
|
AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
|
Active Comparator: AC-1205
AC-1205 liquid, single dose (20 g tricaprilin)
|
AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
|
Active Comparator: AC-1206
AC-1206 liquid, single dose (20 g tricaprilin)
|
AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
|
Experimental: AC-1202
AC-1206 liquid, single dose (20 g tricaprilin)
|
AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total ketones
Time Frame: 1 day
|
Area Under the Curve (AUC) AUC 0 - last
|
1 day
|
Total ketones
Time Frame: 1 day
|
AUC 0 - 4
|
1 day
|
Total ketones
Time Frame: 1 day
|
AUC 0 - 6
|
1 day
|
Total ketones
Time Frame: 1 day
|
AUC 0 - 8
|
1 day
|
Total ketones
Time Frame: 1 day
|
Maximum Plasma Concentration (Cmax)
|
1 day
|
B-hydroxybutyrate
Time Frame: 1 day
|
AUC 0 - last
|
1 day
|
B-hydroxybutyrate
Time Frame: 1 day
|
AUC 0 - 4
|
1 day
|
B-hydroxybutyrate
Time Frame: 1 day
|
AUC 0 - 6
|
1 day
|
B-hydroxybutyrate
Time Frame: 1 day
|
AUC 0 - 8
|
1 day
|
B-hydroxybutyrate
Time Frame: 1 day
|
Cmax
|
1 day
|
Acetoacetate
Time Frame: 1 day
|
AUC 0 - last
|
1 day
|
Acetoacetate
Time Frame: 1 day
|
AUC 0 - 4
|
1 day
|
Acetoacetate
Time Frame: 1 day
|
AUC 0 - 6
|
1 day
|
Acetoacetate
Time Frame: 1 day
|
AUC 0 - 8
|
1 day
|
Acetoacetate
Time Frame: 1 day
|
Cmax
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 13, 2019
Primary Completion (Anticipated)
April 16, 2019
Study Completion (Anticipated)
April 16, 2019
Study Registration Dates
First Submitted
August 16, 2018
First Submitted That Met QC Criteria
August 16, 2018
First Posted (Actual)
August 17, 2018
Study Record Updates
Last Update Posted (Actual)
September 27, 2018
Last Update Submitted That Met QC Criteria
September 25, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AX-18-018_PK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on MCTprocal medical food
-
Abbott NutritionCompleted
-
Romanian Society for Enteral and Parenteral NutritionNot yet recruitingTrauma | Gastroparesis | Muscle Loss | Metabolism | Nutritional Deficiency | Protein Malnutrition | Calorie Malnutrition ProteinRomania
-
Abbott NutritionCompletedHip FractureRussian Federation
-
Faeth TherapeuticsRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic AdenocarcinomaUnited States
-
Vitaflo International, LtdUniversity College London Hospitals; University Medical Center Groningen; University... and other collaboratorsCompletedGlycogen Storage DiseaseUnited States, United Kingdom, France, Netherlands
-
Faeth TherapeuticsWithdrawnMetastatic Colorectal CancerUnited States
-
Targeted Medical PharmaUnknownDiabetic Neuropathy | Chemotherapy Induced Neuropathy | HIV Neuropathy | Trauma Induced NeuropathyUnited States
-
Northwestern UniversityCompletedIrritable Bowel Syndrome | SIBO | Bacterial Overgrowth SyndromeUnited States
-
Pendulum TherapeuticsTerminatedType 2 Diabetes MellitusIreland
-
Solarea Bio, IncRecruiting